Yann Echelard Sells 5,000 Shares of TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the sale, the director directly owned 223,816 shares in the company, valued at approximately $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

TG Therapeutics Trading Up 3.0%

NASDAQ TGTX traded up $0.95 during mid-day trading on Tuesday, reaching $32.98. 1,815,440 shares of the stock were exchanged, compared to its average volume of 2,344,808. The stock has a market cap of $5.24 billion, a P/E ratio of 89.14 and a beta of 1.95. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. TG Therapeutics, Inc. has a one year low of $25.28 and a one year high of $46.48. The stock has a 50 day simple moving average of $33.79 and a 200-day simple moving average of $33.93.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19. The firm had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business’s revenue was up 92.7% compared to the same quarter last year. During the same period last year, the business posted $0.02 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. On average, analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Institutional Trading of TG Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Advisory Services LLC purchased a new position in shares of TG Therapeutics during the second quarter valued at approximately $25,000. Johnson Financial Group Inc. purchased a new position in TG Therapeutics during the 2nd quarter worth $25,000. Danske Bank A S bought a new stake in shares of TG Therapeutics in the 3rd quarter worth $25,000. Optiver Holding B.V. raised its holdings in shares of TG Therapeutics by 3,485.7% in the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 732 shares during the last quarter. Finally, Bessemer Group Inc. lifted its position in shares of TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 486 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on TGTX shares. JPMorgan Chase & Co. boosted their price target on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, November 19th. HC Wainwright started coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price target for the company. Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $50.25.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.